Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
07/2003
07/17/2003WO2003057854A2 Novel proteins and nucleic acids encoding same
07/17/2003WO2003057822A2 Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
07/17/2003WO2003057722A2 Cyclic tetrapeptide compound and use thereof
07/17/2003WO2003057696A1 Deazapurines and uses thereof
07/17/2003WO2003057694A1 Method for producing scopine esters
07/17/2003WO2003057676A1 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists
07/17/2003WO2003057668A1 Nitrogenous cyclic ketone derivative, process for producing the same, and use
07/17/2003WO2003057252A1 Human mast cell-expressed membrane proteins
07/17/2003WO2003057249A1 Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound
07/17/2003WO2003057229A1 Antiviral and antipyretic formulation and the preparation method thereof
07/17/2003WO2003057220A1 Cyclic urea derivatives with 5-ht2c receptor activity
07/17/2003WO2003057211A1 Composition inhibiting matrix-metallproteinases for the treatmentof neoplastic diseases.
07/17/2003WO2003057200A2 Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes
07/17/2003WO2003057198A1 Pharmaceutical formulations with modified release
07/17/2003WO2003057196A1 Drug mixture with enhanced dissolution rate
07/17/2003WO2003057194A1 Sterile filtered nanoparticule formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
07/17/2003WO2003057169A2 4-dedimethylamino tetracycline compounds
07/17/2003WO2003057166A2 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
07/17/2003WO2003057149A2 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones
07/17/2003WO2003057133A2 Herbal composition for treating various disorders including psoriasis, a process for preparation thereof and method for treatment of such disorders
07/17/2003WO2003030827A3 Compositions for and methods of treating and preventing sirs/sepsis
07/17/2003WO2003020325A3 Methods for sterilizing preparations containing albumin
07/17/2003WO2003000896A3 POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-5 GENE
07/17/2003WO2002076434A3 Nicotinic receptor agonists for the treatment of inflammatory diseases
07/17/2003WO2002059286A3 Adenylate cyclases
07/17/2003WO2002046190A3 Sulfonamido ether substituted imidazoquinolines
07/17/2003WO2002026998A3 Hydrolases
07/17/2003US20030134901 Lipoxin compounds and their use in treating cell proliferative disorders
07/17/2003US20030134886 Pharmaceutically active compounds
07/17/2003US20030134876 Inhibiting TNF alpha
07/17/2003US20030134874 Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
07/17/2003US20030134873 8-phenyl-(1,2,4)triazolo(1,5-a)pyridin-2-yl)-benzamide derivatives
07/17/2003US20030134865 Modulation of histone deacetylase
07/17/2003US20030134858 Treatment of inflammation associated disorders, such as arthritis, colon cancer, and Alzheimer's disease
07/17/2003US20030134856 Method and structure for inhibiting activity of serine elastases
07/17/2003US20030134855 P-acylaminomethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2 -yl)-benzamides; treatment of diseases related to the adenosine receptor, such as Alzheimer's disease, depression, drug addiction, Parkinson's and ADHD
07/17/2003US20030134854 Treatment of diseases related to the adenosine receptor, such as Alzheimer's disease, depression, drug addiction, neuroprotection, Parkinson's disease, and attention deficit hyperactivity disorder.
07/17/2003US20030134850 Hydrazinyl and nitrogen oxide pyrazoles
07/17/2003US20030134840 Novel compounds
07/17/2003US20030134839 5-(Alkylidene-cycloalkyl)-and 5-(alkylidene-heterocyclyl)-pyrazoles
07/17/2003US20030134836 Substituted arylamine derivatives and methods of use
07/17/2003US20030134829 X is a ring having at least 4 atoms in the ring; K is hydrocarbyl group; Rh1 is an optional halo group; Rh2 is an optional halo group; at least one of Rh1 and Rh2 is present; Rs is any one of a sulphamate group, a phosphonate,
07/17/2003US20030134810 Delivery of pharmacologically active agents associated with polymeric biocompatible materials. Compositions comprising a first, negatively charged pharmacologically active agent such as an oligonucleotide and a polycationic polymer such as
07/17/2003US20030134805 Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
07/17/2003US20030134796 Antithrombin for the prevention and therapy of vasculoproliferative disorders
07/17/2003US20030134430 Novel amino acid sequences for human caenorhabditis elegans-like protein polypeptides
07/17/2003US20030133988 Immunomodulation accomplished by administration of immunomodulatory polynucleotide/microcarrier complexes comprising 3-6 mer immunomodulatory oligonucleotides
07/17/2003US20030133930 Administering to a patient having an autoimmune disorder an antibody to a B-cell antigens and a carrier; CD22, CD20, CD19, and CD74 or HLA-DR antigen.
07/17/2003US20030133925 Monobactam compositions and methods of use thereof
07/17/2003US20030133911 Pneumovirus ns proteins antagonising the interferon (ifn) response
07/17/2003US20030133880 Powdery pharmaceutical compositions for inhalation
07/17/2003CA2472585A1 Drug mixture with enhanced dissolution rate
07/17/2003CA2472165A1 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists
07/17/2003CA2472151A1 Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound
07/17/2003CA2472111A1 Human mast cell-expressed membrane proteins
07/17/2003CA2471957A1 Cyclic tetrapeptide compound and use thereof
07/17/2003CA2471951A1 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
07/17/2003CA2471490A1 Herbal composition for treating various disorders including psoriasis, a process for preparation thereof and method for treatment of such disorders
07/17/2003CA2470012A1 Novel proteins and nucleic acids encoding same
07/17/2003CA2469162A1 Composition inhibiting matrix-metallproteinases for the treatmentof neoplastic diseases
07/17/2003CA2463798A1 Modulation of immunostimulatory propertiies of oligonucleotide-based compounds by optimal presentation of 5' ends
07/16/2003EP1327630A1 New derivatives of cyano-aryl (or cyanoheteroaryl)-carbonyl-piperazinyl-pyrimidines, their preparation and application as medication
07/16/2003EP1327463A1 Gel comprising Cetirizine and Loratadine for topical application
07/16/2003EP1327452A2 Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics
07/16/2003EP1327449A1 Remedies for ischemic diseases
07/16/2003EP1326986A2 Regulation of human sphingosine kinase-like protein
07/16/2003EP1326869A1 Pyrrole-condensed morphinoid derivatives
07/16/2003EP1326868A1 Morphinoid derivatives as delta-opioid agonists and antagonists
07/16/2003EP1326867A2 Bridged piperazine derivatives
07/16/2003EP1326864A2 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
07/16/2003EP1326863A2 Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
07/16/2003EP1326862A1 Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament
07/16/2003EP1326861A1 Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
07/16/2003EP1326859A1 Quinazoline derivatives with anti-tumour activity
07/16/2003EP1326858A2 Piperidine compounds as anti-allergic
07/16/2003EP1326856A1 Pyridine derivatives with ikb-kinase (ikk-beta) inhibiting activity
07/16/2003EP1326853A1 New thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors
07/16/2003EP1326828A1 Beta-amino acid derivatives as integrin receptor antagonists
07/16/2003EP1326642A2 Catecholamine pharmaceutical compositions and methods
07/16/2003EP1326630A2 Use of glp-1 and glp-2 peptides
07/16/2003EP1326619A2 Pyrrolidine modulators of ccr5 chemokine receptor activity
07/16/2003EP1326612A1 Gatifloxacin pentahydrate
07/16/2003EP1326606A2 Ep4 receptor inhibitors to treat rheumatoid arthritis
07/16/2003EP1326595A2 Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders
07/16/2003EP1326586A1 New pharmaceutical compositions containing epinastine and pseudoephedrine
07/16/2003EP1326585A2 Method for producing powdery formulations
07/16/2003EP1181284B1 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use
07/16/2003EP1165555B1 Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands
07/16/2003EP1155000B1 2-aminopyridines containing fused ring substituents
07/16/2003EP1084104B1 Nitric oxide synthase inhibitors
07/16/2003EP1070069B1 Bicyclic hydroxamic acid derivatives
07/16/2003EP1017385B1 USE OF 4-SUBSTITUTED TETRAHYDROPYRIDINES FOR MAKING MEDICINES ACTING ON TGF-beta 1
07/16/2003EP0832076B1 Novel isoxazoline and isoxazole fibrinogen receptor antagonists
07/16/2003CN1430625A 3-nitrogen-6,7-dioxygen steroids and uses thereof
07/16/2003CN1430620A Macrolides compound
07/16/2003CN1430611A 1,4-diazepan-2,5-dione derivatives and their use as NK-1 receptor antagonists
07/16/2003CN1430610A Substituted 1-aminoalkyl-lactams compound and their use as muscarinic receptor antagonists
07/16/2003CN1430609A Substituted 1-aminoalkyl-lactams compound and their use as muscarinic receptor antagonists
07/16/2003CN1430607A Benzophenones as inhibitors of IL-1 beta and TNF-alpha
07/16/2003CN1430602A Ary-and heteroaryl sulfonates compounds